Nintedanib
Nintedanib is an orally available tyrosine kinase receptor antagonist that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during nintedanib therapy are not uncommon and multiple instances of acute liver injury with symptoms and jaundice have been reported. Nintedanib, which is used to treat idiopathic pulmonary fibrosis and non-small cell lung cancer, is metabolized to a pharmacologically inactive carboxylate derivative, BIBF1202, via hydrolysis and subsequently by glucuronidation to BIBF1202 acyl-glucuronide (BIBF1202-G)
General
Type : Pro-Drug, Drug, Not AlphaBeta Hydrolase target, Piperazine
Chemical_Nomenclature : methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate
Canonical SMILES : CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
InChI : InChI=1S\/C31H33N5O4\/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38\/h4-14,19,33,38H,15-18,20H2,1-3H3
InChIKey : CPMDPSXJELVGJG-UHFFFAOYSA-N
Other name(s) : Vargatef || Intedanib || BIBF-1120
MW : 539.6
Formula : C31H33N5O4
CAS_number : 656247-17-5
PubChem : 135423438
UniChem : CPMDPSXJELVGJG-UHFFFAOYSA-N
Target
Structures : No structure
Families : Carb_B_Chordata
References (1)
| Title : Characterization of Enzymes Involved in Nintedanib Metabolism in Humans - Nakashima_2023_Drug.Metab.Dispos_51_733 |
| Author(s) : Nakashima S , Sato R , Fukami T , Kudo T , Hashiba S , Morinaga G , Nakano M , Ludwig-Schwellinger E , Matsui A , Ishiguro N , Ebner T , Nakajima M |
| Ref : Drug Metabolism & Disposition: The Biological Fate of Chemicals , 51 :733 , 2023 |
| Abstract : |
| PubMedSearch : Nakashima_2023_Drug.Metab.Dispos_51_733 |
| PubMedID: 36927840 |